Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.84M | 13.98M | 11.28M | 8.61M | 14.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 132.60M | 164.13M | 164.74M | 98.56M | 74.57M |
| Operating Income | -132.60M | -164.13M | -164.74M | -98.56M | -74.57M |
| Income Before Tax | -128.02M | -158.33M | -157.66M | -90.79M | -65.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.02M | -158.33M | -157.66M | -90.79M | -65.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.02M | -158.33M | -157.66M | -90.79M | -65.56M |
| EBIT | -132.60M | -164.13M | -164.74M | -98.56M | -74.57M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.10 | -1.37 | -1.38 | -0.81 | -0.58 |
| Normalized Basic EPS | -0.69 | -0.86 | -0.86 | -0.51 | -0.37 |
| EPS Diluted | -1.10 | -1.37 | -1.38 | -0.81 | -0.58 |
| Normalized Diluted EPS | -0.69 | -0.86 | -0.86 | -0.51 | -0.37 |
| Average Basic Shares Outstanding | 116.26M | 115.57M | 114.01M | 112.32M | 112.13M |
| Average Diluted Shares Outstanding | 116.26M | 115.57M | 114.01M | 112.32M | 112.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |